Literature DB >> 15525562

A matrix metalloproteinase inhibitor promotes granuloma formation during the early phase of Mycobacterium tuberculosis pulmonary infection.

A A Izzo1, L S Izzo, J Kasimos, S Majka.   

Abstract

OBJECTIVE: The host response to pulmonary Mycobacterium tuberculosis (Mtb) infection results in granuloma formation in an effort to limit infection, but the host immune cells also provide an environment in which Mtb persists. Granuloma formation requires immune cell infiltration and concurrent extensive remodeling of pulmonary tissue which we hypothesize to be the result of increased matrix metalloproteinases (MMP) activity.
DESIGN: C57BL/6 mice infected with virulent Mtb (H37Rv) via intratracheal inoculation were treated with a synthetic inhibitor of MMP activity (BB-94). Mice were assessed for colony forming units, granuloma morphology, leukocyte recruitment and cytokine levels over 90 days of infection.
RESULTS: BB-94 treated mice had significantly decreased numbers of pulmonary and blood-borne Mtb early during disease, increased collagen deposition within early granulomas and significantly decreased pulmonary leukocyte recruitment when compared to vehicle-treated, Mtb-infected mice. Cytokine expression did not differ significantly between groups.
CONCLUSION: Events of early granuloma formation can be modified by inhibiting MMP activity, by decreasing leukocyte recruitment, a major source of MMPs during infection, enhancing the establishment of granulomas and decreasing blood-borne dissemination of Mtb.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15525562     DOI: 10.1016/j.tube.2004.07.001

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  26 in total

1.  MMPs in tuberculosis: granuloma creators and tissue destroyers.

Authors:  Padmini Salgame
Journal:  J Clin Invest       Date:  2011-04-25       Impact factor: 14.808

Review 2.  The paradox of matrix metalloproteinases in infectious disease.

Authors:  P T G Elkington; C M O'Kane; J S Friedland
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

Review 3.  Host-directed therapeutics for tuberculosis: can we harness the host?

Authors:  Thomas R Hawn; Alastair I Matheson; Stephen N Maley; Omar Vandal
Journal:  Microbiol Mol Biol Rev       Date:  2013-12       Impact factor: 11.056

4.  Streptolysin-O/antibiotics adjunct therapy modulates site-specific expression of extracellular matrix and inflammatory genes in lungs of Rhodococcus equi infected foals.

Authors:  Volkan Gurel; Kristyn Lambert; Allen E Page; Alan T Loynachan; Katherine Huges; John F Timoney; Michael Fettinger; David W Horohov; John McMichael
Journal:  Vet Res Commun       Date:  2013-03-09       Impact factor: 2.459

Review 5.  Pathology and immune reactivity: understanding multidimensionality in pulmonary tuberculosis.

Authors:  Anca Dorhoi; Stefan H E Kaufmann
Journal:  Semin Immunopathol       Date:  2015-10-05       Impact factor: 9.623

6.  Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology.

Authors:  Selvakumar Subbian; Liana Tsenova; Paul O'Brien; Guibin Yang; Mi-Sun Koo; Blas Peixoto; Dorothy Fallows; Jerome B Zeldis; George Muller; Gilla Kaplan
Journal:  Am J Pathol       Date:  2011-05-07       Impact factor: 4.307

7.  Matrix metalloproteinase-2 and matrix metalloproteinase-9 in mice with ocular toxocariasis.

Authors:  Ling-Yuh Shyu; Ke-Min Chen; Shih-Chan Lai
Journal:  Parasitol Res       Date:  2019-01-10       Impact factor: 2.289

8.  Role for matrix metalloproteinase 9 in granuloma formation during pulmonary Mycobacterium tuberculosis infection.

Authors:  Jennifer L Taylor; Jessica M Hattle; Steven A Dreitz; JoLynn M Troudt; Linda S Izzo; Randall J Basaraba; Ian M Orme; Lynn M Matrisian; Angelo A Izzo
Journal:  Infect Immun       Date:  2006-09-18       Impact factor: 3.441

9.  Mycobacterium bovis-BCG vaccination induces specific pulmonary transcriptome biosignatures in mice.

Authors:  Elihu Aranday Cortes; Daryan Kaveh; Javier Nunez-Garcia; Philip J Hogarth; H Martin Vordermeier
Journal:  PLoS One       Date:  2010-06-28       Impact factor: 3.240

Review 10.  Novel adjunctive therapies for the treatment of tuberculosis.

Authors:  A A Ordonez; M Maiga; S Gupta; E A Weinstein; W R Bishai; S K Jain
Journal:  Curr Mol Med       Date:  2014-03       Impact factor: 2.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.